Boehringer Ingelheim ( Boehringer-Ingelheim )


Boehringer Ingelheim's picture

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Learn more about the financial highlights, the corporate vision, the organisation, the Board of Managing Directors and the company's history as well as our engagement for scientific, cultural and environmental purposes.

Boehringer-Ingelheim press release, blog etc

07/10/2018 - 05:44 Boehringer Ingelheim invests more than 200 million to establish strategic production center for Veterinary Public Health in France
07/04/2018 - 14:35 Boehringer Ingelheim extends one-stop-shop service with new fill & finish capabilities in China
06/29/2018 - 18:29 World Scleroderma Day 2018 - Families open up about supporting a loved one with scleroderma, in new video series
06/21/2018 - 22:13 Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
06/18/2018 - 14:51 Boosting animal welfare for small animals: Boehringer Ingelheim expands European Metacam indication to guinea pigs
05/17/2018 - 00:11 Boehringer Ingelheim demonstrates its commitment to farm animal well-being
05/15/2018 - 04:59 Boehringer Ingelheim inaugurates its new integrated Asian Veterinary Research & Development Centre
04/25/2018 - 04:32 Boehringer Ingelheim R&D pushes to transcend disease boundaries
04/25/2018 - 03:11 Boehringer Ingelheim has a very successful 2017 financial year
04/11/2018 - 06:38 Boehringer Ingelheim to invest 65 million in avian vaccines
04/04/2018 - 12:34 Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
03/28/2018 - 02:55 Boehringer Ingelheim announces the 2018 BVDzero Case Awards
03/26/2018 - 03:47 Three Leading Animal Health Companies Join Hands to Launch World-Class Vaccine Joint Venture Targeting Foot-and-Mouth Disease in China
03/19/2018 - 08:31 FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
03/13/2018 - 08:05 Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
02/21/2018 - 01:54 Boehringer Ingelheim: 2018 European PRRS Research Award open for submissions until
02/16/2018 - 06:02 Systemic Sclerosis World Congress: Inspirational patient stories reveal the challenging realities of living with devastating rare disease
02/09/2018 - 06:26 Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimers trials